Protocol development(BASE), protocol implementation(options 1-6), and research laboratory assays (option 8) relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to…
Ended Awarded Last action
- Contract number
- HHSN27200007
- Awardee
-
Baylor College Of Medicine UEI FXKMA43NTV21
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,337,050
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (VTEU) Award Notice · Posted Mar 29, 2012
- Contract value 48% obligated
-
- $1,337,049.62 Current, with exercised options
- $2,791,658.62 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $87,205 | |
| Funding Only Action | -$14,008 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,200,404 | |
| Supplemental Agreement for work within scope | -$112,433 | |
| Original award | $63,449 |
Show all 11
About this award
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Baylor College of Medicine, a private health sciences university in Houston, Texas. The $2,791,658.62 contract is part of the Vaccine and Treatment Evaluation Units (VTEU) program, which supports the development and evaluation of vaccines and treatments for infectious diseases.
The contract requires Baylor to perform protocol development, implementation, and laboratory assays related to a Phase II clinical trial evaluating the safety, reactogenicity, and immunogenicity of an influenza A/H7N9 vaccine in healthy volunteers. The contract has an ultimate completion date of June 30, 2022 and was awarded on January 13, 2016. No set-aside designation was used for this competitively awarded contract.
Description
Protocol development(BASE), protocol implementation(options 1-6), and research laboratory assays (option 8) relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity, and immunogenicity of one or two doses of M-001 followed by one or two doses of an influenza a/H7N9 vaccine in healthy volunteers.
Quick answers
Who was awarded contract HHSN27200007?
HHSN27200007 was awarded to Baylor College Of Medicine by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 13, 2016.
How much is contract HHSN27200007 worth?
The government has obligated $1,337,050 on HHSN27200007. Its potential value, with all options, is $2,791,659.
Is contract HHSN27200007 an order under another contract?
Yes. HHSN27200007 is a delivery order under HHSN272201300015I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200007 competed?
The extent of competition for HHSN27200007 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award